arrow
K

Kimon Tzannis

Alexandra Hospital
H指数:16
被引数:900

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Cabozantinib After Immunotherapy in Advanced Renal Cell Carcinoma. The CARE Study by the Hellenic Gu Cancer Group

免疫疗法后使用卡博扎替尼治疗晚期肾细胞癌。希腊GU癌症小组的CARE研究

2026-09-170
OA
Intravesical Administration of Durvalumab for High-risk Non-muscle-invasive Bladder Cancer: A Phase 2 Study by the Hellenic GU Cancer Group

经膀胱给予 durvalumab 治疗高风险非肌层浸润性膀胱癌:Hellenic GU Cancer Group 开展的一项 II 期研究

2025-03-011
PRE
Nivolumab plus chemoradiotherapy in patients with non-metastatic muscle-invasive bladder cancer (nmMIBC), not undergoing cystectomy: A phase II, randomized study by the Hellenic GU Cancer Group

纳武利尤单抗联合放化疗在未行根治性膀胱切除术的非转移性肌层浸润性膀胱癌(nmMIBC)患者中的应用:一项由希腊GU癌症研究组开展的II期随机研究

2024-09-011
PRE
Demographic and clinical features of critically ill patients with COVID-19 in Greece: The burden of diabetes and obesity
2020-08-0143
OAAI
Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC) (vol 29, pg 361, 2018)
2019-11-0112
OAAI
Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)
2018-02-0155
OAAI
Efficacy and safety of the combination of bevacizumab (BEV) and temsirolimus (TEM) in patients with metastatic renal cancer (mRCC) after first-line anti-VEGF treatment: A Hellenic Cooperative Oncology group (HeCOG) phase II trial

贝伐单抗 (BEV) 和替西罗莫司 (TEM) 联合一线抗VEGF治疗后转移性肾癌 (mRCC) 患者的疗效和安全性: 希腊肿瘤协作组 (HeCOG) II期试验

2016-10-010
OAAI
Adherence to cisplatin-based regimens prescription in fit patients fulfilling platinum eligibility criteria. Impact on outcomes: a retrospective international study of invasive/advanced cancer of the urothelium (RISC) analysis
2016-10-011
OAAI